Paper6146751
Effect of dopamine agonist withdrawal after long-term therapy in prolactinomas. Studies with high-definition computerised tomography.
Johnston DG and 5 others. Lancet, 1984. Cited by 91 papers, by iCite.
Cite this record
ConductScience Library. Effect of dopamine agonist withdrawal after long-term therapy in prolactinomas. Studies with high-definition computerised tomography. Papers, record 6146751. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/6146751
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Effect of dopamine agonist withdrawal after long-term therapy in prolactinomas. Studies with high-definition computerised tomography.
- PubMed
Topics16
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Bromocriptine | Major topic |
| Dopamine | Major topic |
| Ergolines | Major topic |
| Pituitary Neoplasms | Major topic |
| Prolactin | Major topic |
| Adult | |
| Aged | |
| Female | |
| Humans | |
| Male | |
| Middle Aged | |
| Pergolide | |
| Pituitary Function Tests | |
| Pregnancy | |
| Sella Turcica | |
| Tomography, X-Ray Computed |
Source PubMed
Cited by17
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 91 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 36974474 | Approach to the Patient With Prolactinoma. | J Clin Endocrinol Metab | 2023 | https://conductscience.org/library/papers/36974474 | PubMed |
| 34774043 | The recurrence of prolactinoma after withdrawal of dopamine agonist: a systematic review and meta-analysis. | BMC Endocr Disord | 2021 | https://conductscience.org/library/papers/34774043 | PubMed |
| 31556013 | Dopamine agonists in prolactinomas: when to withdraw? | Pituitary | 2020 | https://conductscience.org/library/papers/31556013 | PubMed |
| 29404245 | Pediatric Pituitary Adenoma: Case Series, Review of the Literature, and a Skull Base Treatment Paradigm. | J Neurol Surg B Skull Base | 2018 | https://conductscience.org/library/papers/29404245 | PubMed |
| 26830552 | Withdrawal of dopamine agonist therapy in prolactinomas: In which patients and when? | Pituitary | 2016 | https://conductscience.org/library/papers/26830552 | PubMed |
| 21423245 | Medical treatment of prolactinomas. | Nat Rev Endocrinol | 2011 | https://conductscience.org/library/papers/21423245 | PubMed |
| 21409614 | Long term follow-up of patients with prolactinomas and outcome of dopamine agonist withdrawal: a single center experience. | Pituitary | 2012 | https://conductscience.org/library/papers/21409614 | PubMed |
| 17917811 | Five years follow-up of invasive prolactinomas with special reference to the control of cavernous sinus invasion. | Pituitary | 2008 | https://conductscience.org/library/papers/17917811 | PubMed |
| 12675502 | Medical management of prolactin-secreting pituitary adenomas. | Pituitary | 2002 | https://conductscience.org/library/papers/12675502 | PubMed |
| 12668871 | Hyperprolactinemia in men: clinical and biochemical features and response to treatment. | Endocrine | 2003 | https://conductscience.org/library/papers/12668871 | PubMed |
| 11383485 | Rapid re-expansion of a macroprolactinoma after early discontinuation of bromocriptine. | Pituitary | 2000 | https://conductscience.org/library/papers/11383485 | PubMed |
| 9413808 | Use of cabergoline in the long-term treatment of hyperprolactinemic and acromegalic patients. | J Endocrinol Invest | 1997 | https://conductscience.org/library/papers/9413808 | PubMed |
| 3917709 | Long term suppression of prolactin concentrations after bromocriptine induced regression of pituitary prolactinomas. | Br Med J (Clin Res Ed) | 1985 | https://conductscience.org/library/papers/3917709 | PubMed |
| 2863782 | Present status of neurosurgery in the treatment of prolactinomas. | Neurosurg Rev | 1985 | https://conductscience.org/library/papers/2863782 | PubMed |
| 2863300 | Medical treatment of pituitary adenomas: effects on tumor growth. | J Endocrinol Invest | 1985 | https://conductscience.org/library/papers/2863300 | PubMed |
| 2184010 | Pergolide. A review of its pharmacological properties and therapeutic potential in Parkinson's disease. | Drugs | 1990 | https://conductscience.org/library/papers/2184010 | PubMed |
| 2035258 | Effect of dopamine agonist medication on prolactin producing pituitary adenomas. A morphological study including immunocytochemistry, electron microscopy and in situ hybridization. | Virchows Arch A Pathol Anat Histopathol | 1991 | https://conductscience.org/library/papers/2035258 | PubMed |
Genes1
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes |
|---|---|---|---|
| PRL | 5617 | PubTator's text mining | https://conductscience.org/library/genes/5617 |
Source NCBI Gene
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- References
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/6146751
GET https://conductscience.org/api/papers/v1/6146751/authors